Home » Case Studies » Commercial Strategic Planning » P&MA Assessment to Suppor…

P&MA Assessment to Support BD&L Decision-Making

CBPartners completed a P&MA assessment for an asset in Leber hereditary optic neuropathy to support BD&L decision-making.


To provide BD&L support by assessing the current and future market landscape and the resulting pricing and access potential for PRODUCT X in Leber hereditary optic neuropathy (LHON).



Conduct in-depth interview (IDI) discussions with payers and key opinion leaders (KOLs) to evaluate current treatment practice and price thresholds for LHON, and understand likely payer restrictions as a function of price for a gene therapy.


  • Landscape assessment and analogue assessment across key markets
  • Payer & KOL moderator guides and research stimuli
  • Interim research findings summary
  • Detailed final research findings summary
  • Strategic business development and licensing (BD&L) recommendations and differentiation opportunities

Illustrative Outputs


CBP informed a BD&L strategy in LHON with a detailed P&MA opportunity for each in-scope market.